These two technologies are very good at killing the viruses that are all of the Zika first cousins. In the preliminary studies that have been done on laboratory strains of the Zika virus, including the Thai strain that my colleagues from PHAC have been talking about, these two technologies killed the Zika virus. We are anticipating that this is a way of sterilizing blood and blood products.
The challenge for us is that the technologies that have been developed can only be used on platelets and on plasma. We don't have a technology for red cells. There are two technologies that are in clinical trials. We think that they're coming, but they're not here yet.
If you were talking about giving a red blood cell transfusion to a pregnant woman, you would not be able to reduce the Zika risk by the pathogen inactivation technologies quite yet, but we do see that coming in the near future.